Express Pharma
Home  »  Latest Updates  »  AztraZeneca to launch oncology drug Calquence in India

AztraZeneca to launch oncology drug Calquence in India

It is used to treat mantle cell lymphoma and chronic lymphocytic leukaemia

0 147
Read Article

AstraZeneca Pharma India has received import and market permission in Form CT-20 (Marketing Authorization- Additional Indication) from the Drugs Controller General of India for Acalabrutinib 100 mg capsules (Calquence ). AstraZeneca Pharma India intends to launch Calquence in India on October 21, 2020.

Acalabrutinib 100 mg capsules (Calquence ) is:

  • Indicated for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
  • Indicated for the treatment of patients with chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL).

Leave A Reply

Your email address will not be published.

 Introducing Smart Autoinjector: Changing the paradigm of usability, cost & size
Know More?
close-image